Brainomix is highlighting a study showing how automated noncontrast CT analysis with the company's software may help identify patients with large hemispheric infarction.
These patients are more likely to benefit from intravenous glyburide (Cirara), an investigational therapy from Remedy Pharmaceuticals, according to a post-hoc analysis of the phase III Charm trial presented at the World Stroke Conference in Seoul.
Using its Brainomix 360 Stroke software, the company measured acute infarct volume on noncontrast CT in 428 trial patients. In a subgroup of 191 patients with infarct core volumes below 125 mL, Cirara showed significantly association with improved functional outcomes on the modified Rankin Scale, including a greater likelihood of achieving a score of 0 to 3 at 90 days, the researchers found.
The findings suggest that patients could be selected for trials of the therapy without advanced imaging such as CT perfusion or MRI, Brainomix said. Cirara has not been approved by any regulatory authority.
